ArticleOncotarget2018
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Integrated NGS and ddPCR analysis of RAS/RAF mutations in metastatic colorectal cancer among Kazakhstani patients: a pilot study.Frontiers in medicine · 2026Article
- Genomic landscape of pathogenic mutations in Pakistani population with late-stage colorectal cancer.Pakistan journal of medical sciences · 2025Article
- Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer.Current issues in molecular biology · 2023Article
- Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data.BMC cancer · 2022Article
- Article
- Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report.Frontiers in oncology · 2022Article
- Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.Frontiers in oncology · 2022Review
- The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.Journal of gastrointestinal cancer · 2021Article
- Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice.Annals of translational medicine · 2021Article
- Impact ofBioImpacts : BI · 2021Article
- Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments.Pharmacogenomics and personalized medicine · 2020Review
- Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithFrontiers in oncology · 2020Article
- Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease.Frontiers in oncology · 2020Article
- Article
- Article
- KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015.Heliyon · 2019Article
- Development of an AmpliSeqFrontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC.
methods
resultsIn 63 samples,
conclusionsMost MCRC harboured
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.